Tratamiento del cáncer de próstata en función de la esperanza de vida, la comorbilidad y las guías de práctica clínica

1 BARCELÓ OBRADOR A, RAMOS M, DE LA IGLESIA M, ZAFORTEZA M. Tratamiento del cáncer de próstata en función de la esperanza de vida, la comorbilidad y las guías de práctica clínica. An Sist Sanit Navar 2014; 37: 339-348.

https://doi.org/10.4321/S1137-66272014000300004

2 CHARLSON ME, POMPEI P, ALES KL, MACKENZIE CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.

https://doi.org/10.1016/0021-9681(87)90171-8

3 HEIDENREICH A, BELLMUNT J, BOLLA M ET AL. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71.

https://doi.org/10.1016/j.eururo.2010.10.039

4 MORGIA G, RUSSO GI, TUBARO A et al. Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study. BJU Int 2015; agosto31.doi 10.1111/bju.13307.

https://doi.org/10.1111/bju.13307

5 KUYKENDAL AR, HENDRIX LH, SALLOUM RG, GODLEY PA, CHEN RC. Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications. Ann Oncol 2012; 24: 1338-1343.

https://doi.org/10.1093/annonc/mds618

6 HUNTER GK, REDDY CA, KLEIN EA, KUPELIAN P, ANGERMEIER K, ULCHAKER J et al. Long-Term (10-Year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer. Prostate Cancer 2012; 2012: 1-7.

https://doi.org/10.1155/2012/853487

7 XIONG T, TURNER RM, WEI Y, NEAL DE, LYRATZOPOULOS G, HIGGINS JPT. Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis. BMJ Open 2014 May15; 4 (5): e004285.doi 10.1136

https://doi.org/10.1136/bmjopen-2013-004285

8 RESNICK MJ, KOYAMA T, FAN KH, ALBERTSEN PC, GOODMAN M, HAMILTON AS et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013; 368: 436-445.

https://doi.org/10.1056/NEJMoa1209978

9 SWEENEY CJ, CHEN Y-H, CARDUCCI M, LIN G, JARRARD DF, EISENBERGER M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737-746.

https://doi.org/10.1056/NEJMoa1503747